Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 7 (July)

1. Endoscopic palliation of pancreaticobiliary malignancies.
   Gastrointest Endosc Clin N Am, 15(3): 513-31, ix. [Abstract] [Full-text]
2. The role of endoscopic ultrasonography in the evaluation of pancreatico-biliary cancer.
   Gastrointest Endosc Clin N Am, 15(3): 497-511, viii-ix. [Abstract] [Full-text]
3. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis.
   Int J Radiat Oncol Biol Phys, 62(4): 1021-9. [Abstract] [Full-text]
4. Expression analysis of PMP22/Gas3 in premalignant and malignant pancreatic lesions.
   J Histochem Cytochem, 53(7): 885-93. [Abstract] [Full-text]
5. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.
   Cancer Res, 65(13): 5864-71. [Abstract] [Full-text]
6. Common bile duct obstruction due to a duodenal gastrinoma in a dog.
   Vet J, 170(1): 141-3. [Abstract] [Full-text]
7. Cloning of the hamster p16 gene 5' upstream region and its aberrant methylation patterns in pancreatic cancer.
   Biochem Biophys Res Commun, 333(4): 1249-53. [Abstract] [Full-text]
8. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma.
   Proteomics, 5(10): 2665-79. [Abstract] [Full-text]
9. Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy?
   Pathol Oncol Res, 11(2): 69-73. [Abstract] [Full-text]
10. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.
    Br J Cancer, 93(1): 35-40. [Abstract] [Full-text]
11. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
    Cancer, 104(2): 427-38. [Abstract] [Full-text]
12. Malignant insulinoma: spectrum of unusual clinical features.
    Cancer, 104(2): 264-72. [Abstract] [Full-text]
13. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma.
    Cancer, 104(2): 388-94. [Abstract] [Full-text]
14. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
    Cancer Immunol Immunother, 54(9): 915-25. [Abstract] [Full-text]
15. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
    Surgery, 138(1): 71-7. [Abstract] [Full-text]
16. Locally advanced pancreatic cancer.
    J Clin Oncol, 23(20): 4538-44. [Abstract] [Full-text]
17. Adjuvant treatment for resectable pancreatic cancer.
    J Clin Oncol, 23(20): 4532-7. [Abstract] [Full-text]
18. Molecular markers of early pancreatic cancer.
    J Clin Oncol, 23(20): 4524-31. [Abstract] [Full-text]
19. Intraductal papillary mucinous tumors of the pancreas.
    J Clin Oncol, 23(20): 4518-23. [Abstract] [Full-text]
20. Value of CT criteria in predicting survival in patients with potentially resectable pancreatic head carcinoma.
    J Surg Oncol, 91(1): 33-40. [Abstract] [Full-text]
21. The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells.
    J Surg Oncol, 91(1): 77-83. [Abstract] [Full-text]
22. Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines.
    Genes Chromosomes Cancer, 44(1): 37-51. [Abstract] [Full-text]
23. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
    Cancer Res, 65(14): 6388-93. [Abstract] [Full-text]
24. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions.
    Cancer Res, 65(14): 6011-6. [Abstract] [Full-text]
25. The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996-1999.
    Am J Epidemiol, 162(3): 222-8. [Abstract] [Full-text]
26. Differences in survival by histologic type of pancreatic cancer.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1766-73. [Abstract] [Full-text]
27. Identification of peptides that bind to irradiated pancreatic tumor cells.
    Int J Radiat Oncol Biol Phys, 62(5): 1497-503. [Abstract] [Full-text]
28. Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas.
    Int J Radiat Oncol Biol Phys, 62(5): 1357-62. [Abstract] [Full-text]
29. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
    Int J Radiat Oncol Biol Phys, 62(5): 1351-6. [Abstract] [Full-text]
30. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
    Int J Radiat Oncol Biol Phys, 62(5): 1345-50. [Abstract] [Full-text]
31. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
    Br J Cancer, 93(2): 195-9. [Abstract] [Full-text]
32. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
    Br J Cancer, 93(2): 185-9. [Abstract] [Full-text]
33. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.
    Br J Cancer, 93(2): 233-41. [Abstract] [Full-text]
34. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
    Mod Pathol, 18(8): 1034-42. [Abstract] [Full-text]
35. Impact of reconstruction methods on outcome of pancreatoduodenectomy in pancreatic cancer patients.
    World J Surg, 29(4): 500-4. [Abstract] [Full-text]
36. Expression of mutated cationic trypsinogen reduces cellular viability in AR4-2J cells.
    Biochem Biophys Res Commun, 334(2): 721-8. [Abstract] [Full-text]
37. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer.
    Mol Carcinog, 43(4): 215-24. [Abstract] [Full-text]
38. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Mol Cancer Res, 3(7): 413-23. [Abstract] [Full-text]
39. Probing of specific binding of synthetic sulfonylurea with the insulinoma cell line MIN6.
    J Biochem (Tokyo), 138(1): 21-5. [Abstract] [Full-text]
40. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas.
    J Clin Pathol, 58(8): 845-52. [Abstract] [Full-text]
41. Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes.
    Oncogene, 24(32): 5079-88. [Abstract] [Full-text]

© 2004-2008 Pancreatic Cancer Research Today. All Rights Reserved.